Vyleesi Legal and Patent Challenges

FDA Approval and the Regulatory Path

The FDA approved bremelanotide on June 19, 2019, under NDA 210557, making it the second drug ever approved for HSDD in premenopausal women, after flibanserin (Addyi) in 2015. The approval was based on two replicate Phase 3 trials in the RECONNECT program, which enrolled 1,247 premenopausal women with generalized acquired HSDD [1].

In RECONNECT, women self-administered bremelanotide 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity. At 24 weeks, bremelanotide produced a statistically significant increase in the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) desire item score versus placebo (mean change -0.7 vs. -0.4, P<0.001) and a significant increase in satisfying sexual events [1]. The effect size was modest. This point became a recurring theme in the drug's commercial and legal narrative.

The FDA's review included an advisory committee meeting in which panelists debated whether the clinical benefit was large enough to justify the risks. The panel voted 14-to-2 in favor of approval but flagged blood pressure elevations as a concern requiring close label language [2].

Labeling Restrictions That Shaped the Market

Vyleesi's FDA label contains several prescribing constraints that have no parallel in the flibanserin label, and these restrictions have had direct consequences for commercial adoption.

The label caps dosing at 8 injections per calendar month. It warns against use in patients with uncontrolled hypertension or known cardiovascular disease. It specifies that bremelanotide is not approved for use in postmenopausal women, a population that accounts for a large share of HSDD diagnoses. The label also notes transient blood pressure increases: in RECONNECT, systolic blood pressure rose by a mean of 4 mmHg and diastolic by 2 mmHg after injection, with peak effects occurring approximately 2 to 3 hours post-dose [1][2].

These restrictions meant that the prescribing population was narrower than for oral competitors. Clinicians had to counsel patients about self-injection technique on top of safety monitoring. The result was a steep adoption curve that neither Palatin nor its commercial partner could flatten quickly enough.

Patent Portfolio and Intellectual Property Disputes

Palatin Technologies built a layered patent estate around bremelanotide spanning composition of matter, formulation, and method-of-use claims. The core patents listed in the FDA Orange Book include U.S. Patent Nos. 8,487,073 and 9,221,867, covering the cyclic peptide structure and its use in treating sexual dysfunction. These patents are scheduled to expire in the early 2030s [3].

Palatin's IP strategy relied on the structural novelty of bremelanotide as a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone. Because the molecule targets the MC4R receptor through a mechanism distinct from PDE5 inhibitors or serotonin modulators, composition-of-matter claims were granted without the prior-art challenges that plagued flibanserin's patent filings.

No Paragraph IV ANDA challenge (the typical generic drug patent challenge under the Hatch-Waxman Act) has been publicly filed against Vyleesi as of early 2026. The small commercial market may explain why generic manufacturers have not yet tested Palatin's patents. A drug with limited sales volume presents a less attractive target for the costly litigation that Paragraph IV filings require.

Palatin also pursued international patent protection, filing applications through the Patent Cooperation Treaty (PCT) route. The European Medicines Agency (EMA) has not approved bremelanotide; Palatin has not submitted an EU Marketing Authorization Application, which limits the practical value of European patent holdings for now.

The AMAG Commercialization Agreement and Its Collapse

Palatin licensed U.S. commercial rights for Vyleesi to AMAG Pharmaceuticals in a deal structured with milestone payments and royalties. AMAG launched Vyleesi in the fall of 2019 with a list price of approximately $899 per auto-injector carton (4 doses). Sales were immediately disappointing.

AMAG reported net Vyleesi revenue of just $2.2 million for Q4 2019. By early 2020, AMAG itself was struggling financially across its portfolio and became an acquisition target. Covis Pharma Group acquired AMAG in November 2020. Covis, a private company focused on specialty pharmaceuticals, has maintained Vyleesi's availability but has not invested in a large-scale direct-to-consumer marketing campaign.

The commercial shortfall created a secondary legal question: whether Palatin's milestone payments and royalty structure would ever generate meaningful returns. Palatin's SEC filings from 2020 and 2021 disclosed that multiple development and commercial milestones tied to Vyleesi remained unmet [4]. This dynamic pushed Palatin to refocus its pipeline on MC4R-based compounds for other indications, including obesity, where the addressable market is larger.

Cardiovascular Safety Signals and Post-Market Surveillance

The transient blood pressure elevation observed in RECONNECT remained the primary safety concern after approval. The FDA required Palatin to include a Warnings and Precautions section noting that bremelanotide caused dose-dependent increases in blood pressure and decreases in heart rate [2].

In RECONNECT, 0.8% of bremelanotide-treated patients discontinued due to hypertension-related adverse events versus 0% in the placebo group [1]. Among patients with pre-existing controlled hypertension, the blood pressure increases were more pronounced. The FDA Adverse Event Reporting System (FAERS) has captured additional post-market reports of hypertensive episodes, nausea (reported by approximately 40% of patients in trials), and injection-site reactions [5].

Nausea was the single most common adverse event. In the RECONNECT trials, 40.0% of bremelanotide-treated women reported nausea compared to 1.3% in the placebo arm [1]. The nausea was generally mild to moderate, and it diminished with repeated dosing for most patients. But the symptom contributed to high dropout rates: in the open-label extension, approximately 8% of patients discontinued because of nausea [1].

The FDA has not required a Risk Evaluation and Mitigation Strategy (REMS) for Vyleesi, distinguishing it from flibanserin, which carried a REMS requiring prescriber and pharmacy certification due to alcohol interaction risks. The absence of a REMS was a regulatory win for Palatin, but the blood pressure warnings and injection-only delivery route functioned as practical barriers to broad prescribing.

Comparison to Flibanserin's Regulatory and Legal History

Flibanserin (Addyi), approved in 2015, faced its own extensive legal and regulatory battles that provide a useful contrast. Flibanserin was rejected twice by the FDA (in 2010 and 2013) before Sprout Pharmaceuticals mounted a public advocacy campaign and secured approval with a REMS [6]. Vyleesi was approved on its first submission.

The patent landscapes differ as well. Flibanserin's composition-of-matter patents were originally held by Boehringer Ingelheim and later transferred through two acquisitions. Generic challenges to flibanserin began in 2021. Bremelanotide's patent estate has faced no such challenge, partly because the molecule's commercial performance has not attracted generic interest.

From a safety regulation standpoint, flibanserin carries a black box warning about severe hypotension and syncope when combined with alcohol or moderate-to-strong CYP3A4 inhibitors. Vyleesi has no black box warning. This distinction gave bremelanotide a theoretical safety-labeling advantage, but the self-injection route and nausea profile offset that advantage in clinical practice.

According to the Endocrine Society, both bremelanotide and flibanserin are options for premenopausal HSDD, but neither drug has achieved widespread clinical adoption due to modest efficacy, side effect profiles, and insurance coverage gaps [7].

Insurance Coverage and Access Barriers

Payer coverage for Vyleesi has been inconsistent. Many commercial insurers classify it as a lifestyle drug and exclude it from formularies. Prior authorization requirements are common even when coverage exists. The self-pay cost of roughly $225 per dose has placed it out of reach for patients without coverage.

Palatin and its partners have offered copay assistance programs, but these do not address the fundamental coverage gap. The Centers for Medicare & Medicaid Services (CMS) does not cover Vyleesi under Medicare Part D for most beneficiaries, as the approved indication is limited to premenopausal women, a population that is overwhelmingly under 65.

The coverage situation created a feedback loop: low prescribing volumes reduced the data available for outcomes-based negotiations with insurers, which in turn kept coverage restrictive.

Ongoing Legal and Regulatory Considerations

Several legal and regulatory threads remain active or plausible. First, any future Paragraph IV ANDA filing against Palatin's Orange Book patents would trigger a 30-month stay and litigation in the U.S. District Court, likely in New Jersey where Palatin is headquartered. The strength of Palatin's composition-of-matter claims, given bremelanotide's unique cyclic peptide structure, would make such litigation complex.

Second, Palatin has explored supplemental NDAs (sNDAs) for additional indications and populations. An expansion to postmenopausal women would require a new Phase 3 trial and could alter the drug's patent-term calculus through pediatric or other exclusivity extensions, though female sexual dysfunction drugs have not historically qualified for pediatric exclusivity.

Third, the FDA's Sentinel Initiative continues to monitor bremelanotide for long-term cardiovascular outcomes. Any emerging signal of sustained hypertension or cardiovascular events could trigger a label change or new risk communication, which would have downstream effects on both prescribing and any generic approval pathway.

Dr. Sheryl Kingsberg, a lead RECONNECT investigator, noted in the original trial publication that "bremelanotide represents a first-in-class mechanism for HSDD, but the clinical benefit must be weighed against the tolerability profile, particularly nausea and blood pressure effects" [1]. That calculus continues to define the drug's regulatory and commercial position.

What Palatin's MC4R Pipeline Means for the Patent Estate

Palatin has leveraged its melanocortin receptor expertise to develop next-generation MC4R compounds, including PL-8177 for inflammatory bowel disease and PL-9643 for dry eye disease. These programs do not directly affect Vyleesi's patent estate, but they demonstrate ongoing investment in the receptor class and could generate new composition-of-matter filings that reference the bremelanotide scaffold.

If Palatin secures approvals for additional MC4R compounds, it could create a broader patent thicket around the melanocortin receptor space. This strategy would not extend Vyleesi's own patent life, but it could complicate freedom-to-operate analyses for any generic manufacturer seeking to enter the bremelanotide market.

Palatin reported in its 2025 annual filing with the SEC that royalty income from Vyleesi remained below expectations and that the company's long-term strategy centers on its pipeline compounds rather than Vyleesi lifecycle management [4].